Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HCW Biologics Inc (HCWB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: HCWB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -5.77% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.95M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 162041 | Beta 0.84 | 52 Weeks Range 0.21 - 1.93 | Updated Date 03/30/2025 |
52 Weeks Range 0.21 - 1.93 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.05 |
Earnings Date
Report Date 2025-03-28 | When - | Estimate - | Actual -0.0797 |
Profitability
Profit Margin - | Operating Margin (TTM) -2235.75% |
Management Effectiveness
Return on Assets (TTM) -70.09% | Return on Equity (TTM) -344.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21530666 | Price to Sales(TTM) 3.61 |
Enterprise Value 21530666 | Price to Sales(TTM) 3.61 | ||
Enterprise Value to Revenue 8.5 | Enterprise Value to EBITDA -3.63 | Shares Outstanding 37823400 | Shares Floating 17849994 |
Shares Outstanding 37823400 | Shares Floating 17849994 | ||
Percent Insiders 52.3 | Percent Institutions 3.18 |
Analyst Ratings
Rating 4 | Target Price 3 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
HCW Biologics Inc
Company Overview
History and Background
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to address unmet needs in chronic, low-grade inflammatory and age-related diseases. Founded in 2018, it is still in early stages and focusing on development programs.
Core Business Areas
- TOBI Platform: The company's core technology platform, TOBI (Tissue Organoid-Based Integrated Discovery), is used to discover and develop immunotherapies.
- Therapeutic Development: HCW Biologics is engaged in the development of various therapeutic candidates targeting inflammatory and age-related diseases, with its lead program focused on cancer.
Leadership and Structure
The leadership team consists of experienced scientists and business executives in the biopharmaceutical industry. Specific organizational structure details are publicly available in regulatory filings.
Top Products and Market Share
Key Offerings
- HCW9218: HCW9218 is an investigational immunotherapy being developed for various cancers. It is in early stages. No market share or revenue data is available. Competitors include companies developing cancer immunotherapies (e.g., Merck, BMS, Roche).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the immunotherapy segment, is experiencing rapid growth driven by advancements in science and technology. Companies are focused on developing novel therapies for various diseases.
Positioning
HCW Biologics is a relatively small player focusing on the discovery and development of novel immunotherapies using its proprietary TOBI platform. Its competitive advantage, if proven, is the unique approach of the TOBI platform in targeting age-related inflammation.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy is estimated to be tens of billions of dollars annually. HCW Biologics, being in the early stages, has a small initial presence and is positioning itself to capture a share of this market.
Upturn SWOT Analysis
Strengths
- Proprietary TOBI platform for discovering novel immunotherapies
- Experienced management team
- Focus on addressing unmet medical needs in inflammatory and age-related diseases
Weaknesses
- Early-stage company with no products currently generating revenue
- High dependence on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial results leading to regulatory approvals
- Expansion of the TOBI platform to address new therapeutic areas
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies with more resources
- Regulatory hurdles and changes in healthcare policies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
Competitive Landscape
HCW Biologics faces intense competition from established pharmaceutical companies with significantly greater resources and established product portfolios. Its success hinges on demonstrating the superiority of its TOBI platform and therapeutic candidates.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is in the early stages of development.
Future Projections: Future growth projections are highly dependent on the successful development and commercialization of its therapeutic candidates. Analyst estimates vary.
Recent Initiatives: Recent initiatives include progressing HCW9218 through clinical trials and exploring partnerships for further development.
Summary
HCW Biologics is an early-stage biopharmaceutical company with a promising technology platform, but it faces significant risks and challenges. Its success depends on successful clinical trials and partnerships. The company's TOBI platform offers potential advantages, but it must overcome competition from larger, well-established players and avoid the pitfalls of clinical trials.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
XBI
SPDR® S&P Biotech ETF
XBI
SPDR® S&P Biotech ETF
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor. Market share data are estimates based on available information and are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About HCW Biologics Inc
Exchange NASDAQ | Headquaters Miramar, FL, United States | ||
IPO Launch date 2021-07-20 | Founder, CEO, Director & Secretary Dr. Hing C. Wong Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 45 | Website https://www.hcwbiologics.com |
Full time employees 45 | Website https://www.hcwbiologics.com | ||
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.